Business Daily Media

Business Marketing

.

Hua Medicine Successfully Completes Its Registration Phase III Trials; Announces 52-Week Results for DAWN (HMM0302), Dorzagliatin's Phase III Combination with Metformin Trial

  • Written by ACN Newswire - Press Releases
SHANGHAI, CHINA, Dec 18, 2020 - (ACN Newswire) - Hua Medicine (the "Company", Stock Code: 2552.HK), a leading innovative drug development company focused on developing novel therapies for the treatment of diabetes, today announced:

Hua Medicine Successfully Completes Its Registration Phase III Trials; Announces 52-Week Results for DAWN (HMM0302), Dorzagliatin's Phase III Combination with Metformin Trial

- Successfully completes two Phase III 53-week registration trials in over 1,200+ Chinese patients in the midst of

Read more //?#

Popular

Medius delivers seamless cross-border payments with TransferMate

STOCKHOLM, June 30, 2021 – Medius, a leading provider of spend management solutions, is announcing its partnership with TransferMate, the leader in payments infrastructure as a service, to offer Medius customers an integrate...

Product Assembly Services: Does Your Product Need Help?

Product Assembly Services are services that assist companies in producing new products in order to meet customer demand. These types of products can be complex, electro-mechanical, or automated. The assembly process is usually...

What’s next for businesses after surviving the pandemic?

As we enter our third year living with COVID, businesses’ survival strategies are starting to enter maturity, giving companies room to refocus their efforts from pure survival to the projects they were working on pre-pandemic...